Literature DB >> 27469182

Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis.

Meghana Nitin Sathe1, Alvin Jay Freeman2.   

Abstract

Pulmonary disease is the primary cause of morbidity and mortality in people with cystic fibrosis (CF), but significant involvement within gastrointestinal, pancreatic, and hepatobiliary systems occurs as well. As in the airways, defects in CFTR alter epithelial surface fluid, mucus viscosity, and pH, increasing risk of stasis through the various hollow epithelial-lined structures of the gastrointestinal tract. This exerts secondary influences that are responsible for most gastrointestinal, pancreatic, and hepatobiliary manifestations of CF. Understanding these gastrointestinal morbidities of CF is essential in understanding and treating CF as a multisystem disease process and improving overall patient care.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CF and GI manifestations; CF pancreas; CFLD (CF liver disease); PERT (pancreatic enzyme replacement therapy)

Mesh:

Substances:

Year:  2016        PMID: 27469182     DOI: 10.1016/j.pcl.2016.04.008

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  9 in total

1.  Epidemiology of Eosinophilic Esophagitis in Patients with Cystic Fibrosis: A Population-Based 5-Year Study.

Authors:  Omar Alaber; Ramy Sabe; Virginia Baez-Socorro; Senthilkumar Sankararaman; Erica Roesch; Thomas J Sferra
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2022-07-06

2.  Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis.

Authors:  Alex H Gifford; Julie L Sanville; Meghana Sathe; Sonya L Heltshe; Christopher H Goss
Journal:  Pediatr Pulmonol       Date:  2021-04-26

Review 3.  Recurrent Pneumonia in Children: A Reasoned Diagnostic Approach and a Single Centre Experience.

Authors:  Silvia Montella; Adele Corcione; Francesca Santamaria
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

4.  Serum Level of D-Lactate in Patients with Cystic Fibrosis: Preliminary Data.

Authors:  Sabina Więcek; Jerzy Chudek; Halina Woś; Maria Bożentowicz-Wikarek; Bożena Kordys-Darmolinska; Urszula Grzybowska-Chlebowczyk
Journal:  Dis Markers       Date:  2018-07-12       Impact factor: 3.434

5.  Coming Full Circle: Reflections and Inspirations from a Cystic Fibrosis Patient Scientist Panel.

Authors:  Alexandra Xan C H Nowakowski; Gabriella Ella Balasa; Miriam F Figueira; Francis Tré J LaRosa; James M J Lawlor
Journal:  Inquiry       Date:  2022 Jan-Dec       Impact factor: 2.099

Review 6.  Personalized or Precision Medicine? The Example of Cystic Fibrosis.

Authors:  Fernando A L Marson; Carmen S Bertuzzo; José D Ribeiro
Journal:  Front Pharmacol       Date:  2017-06-20       Impact factor: 5.810

7.  Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents.

Authors:  Ana Luiza Melo Dos Santos; Helen de Melo Santos; Marina Bettiol Nogueira; Hugo Tadashi Oshiro Távora; Maria de Lourdes Jaborandy Paim da Cunha; Renata Belém Pessoa de Melo Seixas; Luciana de Freitas Velloso Monte; Elisa de Carvalho
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2018-10-10

8.  CFTR dysregulation drives active selection of the gut microbiome.

Authors:  Stacey M Meeker; Kevin S Mears; Naseer Sangwan; Mitchell J Brittnacher; Eli J Weiss; Piper M Treuting; Nicholas Tolley; Christopher E Pope; Kyle R Hager; Anh T Vo; Jisun Paik; Charles W Frevert; Hillary S Hayden; Lucas R Hoffman; Samuel I Miller; Adeline M Hajjar
Journal:  PLoS Pathog       Date:  2020-01-21       Impact factor: 6.823

9.  Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies.

Authors:  Marina A Stefano; Rosana E Poderoso; Jochen G Mainz; Jose D Ribeiro; Antonio F Ribeiro; Elizete Aparecida Lomazi
Journal:  J Pediatr (Rio J)       Date:  2020-05-08       Impact factor: 2.990

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.